BioSpace Movers & Shakers

BioSpace
|
March 11, 2022
X min read
BioSpace
|
March 11, 2022
Share on Social
share on Twitter or X
share on Linkedin
share onFacebook
share on Bluesky

More like this

News

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now
Press

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now
News

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy

January 14, 2026

Endpoints

Read Now
Press

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy

January 14, 2026

Endpoints

Read Now
News

Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 15, 2025

Read Now
Press

Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 15, 2025

Read Now
See More